{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-165409","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2023-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.299446+00:00","generated_at":"2026-06-14T02:55:47.471128+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CalciMedica receives Nasdaq approval, relisting starts June 14, 2023 under CALC","bullets":["Nasdaq approved relisting on Capital Market; trading begins June 14, 2023.","Common stock to trade under ticker 'CALC' on Nasdaq after OTCQB trading.","CEO cites improved liquidity, broader investor access, and support for clinical strategy.","Company continues Phase 2 trials of Auxora for inflammatory diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-165409","json":"https://secwatch.observer/filing/0001193125-23-165409.json","markdown":"https://secwatch.observer/filing/0001193125-23-165409.md","text":"https://secwatch.observer/filing/0001193125-23-165409.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523165409/0001193125-23-165409-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523165409/d506112d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T02:55:47.471128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}